CD47 and ovarian carcinoma: In the expansion phase, subjects were enrolled into one of the five cohorts: recurrent glioblastoma (rGBM), pancreatic cancer, ovarian cancer, TNBC, and a high-CD36 and high-CD47 basket cohort.